ClinicalTrials.gg
CompletedNCT06547554Updated Nov 28, 2025

A DDI Study to Investigate PK and Safety of Cefiderocol in Combination With Xeruborbactam in Healthy Adult Participants

A Phase 1 interventional study of Xeruborbactam and Cefiderocol in Bacterial Infections, sponsored by Qpex Biopharma, Inc.. Completed at 1 site in United States. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-11-28.

Sponsored by Qpex Biopharma, Inc. (part of Shionogi) · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Primary completion was Oct 2025, 1 year ago, and no results have been posted to the registry.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
60
Allocation
Randomized
Ages
18 Years to 55 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 10 studies in Bacterial Infections by Shionogi — none open to participants now, none under way, none of them phase 3. Bacterial Infections · Shionogi.

Started
2024
with 2 others
Phase 1
9 of 10
none open now
Registered
9th of 10
by date

Among the 10 studies in Bacterial Infections by Shionogi, this one is one of 3 that started in 2024, is one of 9 in phase 1, and was the 9th registered.

Bacterial Infections

585 studies on the registry are indexed under Bacterial Infections; 84 are open to participants now.

Browse Bacterial Infections studies →

Open to participants now

None of the 10 studies in Bacterial Infections by Shionogi is open now. The open studies under Bacterial Infections, anywhere →

Where they have run

Who these studies take

Of the 57 Bacterial Infections studies recruiting now, 38 (67%) set no upper age limit and 14 (25%) stop at 75 or younger; 19 take children under 18; 6 take healthy volunteers.

This study: 18 Years to 55 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 10 studies in Bacterial Infections by Shionogi as a file.
02

Study summary

A phase 1, randomized, double blind, placebo controlled drug-drug interaction, pharmacokinetics and safety study of cefiderocol in combination with xeruborbactam in healthy adult participants

Read the detailed description

Qpex Biopharma, Inc. is developing xeruborbactam, a new boron-based beta-lactamase inhibitor with activity against both serine and metallo-beta-lactamases in combination with a beta-lactam antibiotic.

Cefiderocol is a cephalosporin antibiotic approved in the US for the treatment of complicated urinary tract infections including pyelonephritis, and hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia.

03

Conditions studied

  • Bacterial Infections

Browse trials for

Keywords

  • beta-lactamase inhibitor
04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male or female, 18 to 55 years of age (inclusive) at the time of signing the .
  • (BMI) ≥ 18.5 and 32 (kg/m2) and weight between 55.0 and 100.0 kg (inclusive)
  • Subjects must be judged to be in good health based upon the results of a medical history, physical examination, vital signs, 12-lead and laboratory profile
  • Voluntary consent to participate in the study.

Exclusion criteria

Exclusion Criteria:

  • History or presence of significant cardiovascular, pulmonary, hepatic, renal, hematological, gastrointestinal, endocrine, immunologic, dermatologic, neurological, or psychiatric disease.
  • A subject with active drug or alcohol abuse within 2 years prior to the initial study drug administration
  • Females who are pregnant or lactating
  • Documented reaction or anaphylaxis to any medication. History of any severe hypersensitivity, anaphylaxis, or allergic reaction to cefiderocol or any other beta-lactam antibacterial drugs, or any other used in the formulation (eg, cephalosporins, penicillins, carbapenems, or monobactams)
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
60 participants (actual)

Study arms

  • Experimental
    Single Dose Cohorts

    Administered single fixed dose of Xeruborbactam Administered single fixed dose of Cefiderocol Administered single fixed dose of a combination of Xeruborbactam and Cefiderocol.

    Drug: Xeruborbactam · Drug: Cefiderocol · Drug: Xeruborbactam/Cefiderocol

  • Experimental
    Multiple Dose Cohort Xeruborbactam

    Administered multiple fixed doses of Xeruborbactam

    Drug: Xeruborbactam

  • Experimental
    Multiple Dose Cohort Cefiderocol

    Administered multiple fixed doses of Cefiderocol

    Drug: Cefiderocol

  • Experimental
    Multiple Dose Cohort Cefiderocol and Xeruborbactam

    Administered multiple fixed doses of a combination of Cefiderocol and Xeruborbactam.

    Drug: Xeruborbactam/Cefiderocol

  • Placebo comparator
    Multiple Dose Cohort Placebo

    Administered multiple fixed volumes of a placebo comparator

    Drug: Dextrose 5% in water

  • Placebo comparator
    Single Dose Cohorts Placebo

    Administered single fixed volume of a placebo comparator

    Drug: Dextrose 5% in water

Interventions

06

What researchers measure

Primary outcomes

  1. The incidence and nature of treatment emergent adverse events (TEAE)

    Summarized by cohort

    Time frame: up to day 17 or up to day 21

  2. Number of patients with changes from baseline in safety parameters

    Summarized by cohort

    Time frame: up to day 17 or up to day 21

  3. Maximum plasma concentration (Cmax)

    Summarized by cohort

    Time frame: up to day 17 or up to day 21

  4. Time to maximum plasma concentration (Tmax)

    Summarized by cohort

    Time frame: up to day 17 or up to day 21

  5. Area under the plasma concentration versus time curve (AUC)

    Summarized by cohort

    Time frame: up to day 17 or up to day 21

  6. Terminal elimination half-life (t1/2,z)

    Summarized by cohort

    Time frame: up to day 17 or up to day 21

  7. Terminal elimination rate constant (λz)

    Summarized by cohort

    Time frame: up to day 17 or up to day 21

  8. Total clearance (CL)

    Summarized by cohort

    Time frame: up to day 17 or up to day 21

  9. Renal clearance (CLR)

    Summarized by cohort

    Time frame: up to day 17 or up to day 21

  10. Fraction of dose excreted in urine (Feu)

    Summarized by cohort

    Time frame: up to day 17 or up to day 21

07

Study locations

1 site
  • Minneapolis Clinic
    Minneapolis, Minnesota 55114, United States
08

References and documents

Publications

  • Gonzalez-Pinto L, Gomis-Font MA, Perez-Rodriguez G, Blanco-Martin T, Rodriguez-Pallares S, Sanchez-Pena L, Beceiro A, Bou G, Jeannot K, Oliver A, Arca-Suarez J. Contribution of mutational resistance mechanisms and acquired beta-lactamases to cefiderocol/xeruborbactam susceptibility in Pseudomonas aeruginosa. Antimicrob Agents Chemother. 2025 Dec 10;69(12):e0104825. doi: 10.1128/aac.01048-25. Epub 2025 Oct 21. PubMed 41118352 ↗

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Sep 2024 to primary completion in Oct 2025, 13 months.

Of 52 industry-sponsored phase 1 interventional studies under Bacterial Infections, half reached primary completion within 8 months of starting (the median), counting those still running; a quarter within 3 and three quarters within 13. This study's 13 months is above that.

Counting every sponsor, half of 67 studies reached it within 9 months; a quarter within 4 and three quarters within 15.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 2, 2024
First posted
Aug 9, 2024
StartActual
Sep 4, 2024
Primary completionActual
Oct 27, 2025
CompletionActual
Oct 27, 2025
Last update
Nov 28, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 28, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06547554
Collaborators
Shionogi Inc., Biomedical Advanced Research and Development Authority
Responsible party
Sponsor
First posted
Aug 9, 2024
Start date
Sep 4, 2024
Primary completion
Oct 27, 2025
Completion
Oct 27, 2025
Last update
Nov 28, 2025

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Xeruborbactam · Cefiderocol

Start the discussion